IP Library Granted Patent US 8,071,745
Granted Patent B2
US 8,071,745 · App. 11/739,734 · Granted Dec 6, 2011

Polynucleotides encoding rod-derived cone viability factor (rdcvf) and methods of using the same

Assignees: Novartis AG; Universite de Strasbourg
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,745
App. No.
11/739,734
Granted
Dec 6, 2011
Kind
B2
Abstract

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.

Claims (8)

1. An isolated nucleic acid molecule encoding Rod-Derived Clone Viability Factor 1 or 2 (RDCVF1 or RDCVF2) consisting of the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3.

2. An isolated host cell comprising the isolated nucleic acid molecule according to claim 1 .

3. A vector molecule comprising the isolated nucleic acid molecule according to claim 1 .

4. The vector molecule according to claim 3 further comprising transcriptional control sequences.

5. An isolated host cell comprising the vector molecule according to claim 3 .

6. An isolated vertebrate host cell which can be propagated in vitro and which is capable upon growth in culture of producing a polypeptide, wherein said cell comprises at least one transcriptional control sequence, wherein said at least one transcriptional control sequence controls transcription of the isolated nucleic acid molecule according to claim 1 .

7. The vertebrate cell according to claim 6 wherein said at least one transcriptional control sequence is a non-human transcriptional control sequence.

8. A method for producing Rod-Derived Cone Viability Factor 1 (RDCVF1) or Rod-Derived Cone Viability Factor 2 (RDCVF2) polypeptides comprising: culturing a host cell having incorporated therein the expression vector according to claim 3 under conditions sufficient for expression of RDCVF1 or RDCVF2 polypeptides in the host cell, thereby causing the production of the expressed polypeptide; and recovering the polypeptide produced by said cell.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT OPHTHALMICS CORPORATION
Reel/Frame 054983/0577 →
SECURITY AGREEMENT Recorded Sep 17, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0182 →
SECURITY AGREEMENT Recorded Aug 15, 2013
From: WELLSTAT OPHTHALMICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031030/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2010
From: LEVEILLARD, THIERRY; SAHEL, JOSE ALAIN; MOHAND-SAID, SADDEK; HICKS, DAVID
To: NOVARTIS AG; UNIVERSITE LOUIS PASTEUR
Reel/Frame 024180/0767 →
CHANGE OF NAME Recorded Apr 2, 2010
From: UNIVERSITE LOUIS PASTEUR
To: UNIVERSITE DE STRASBOURG
Reel/Frame 024180/0795 →
Priority Claims (1)
FR 01 04712 · Apr 6, 2001 · national
Continuity (2)
Division 10473008
Related Publication 20090062188A1 · Mar 5, 2009